Leerink reiterates Hims and Hers stock rating on peptide outlook

Leerink Partners reiterated a Market Perform rating on Hims & Hers with a $25 price target, versus the stock's current $26.60 price. The key catalyst is an upcoming FDA Advisory Committee meeting on injectable peptides, which could expand Hims' peptide-based growth opportunities if restrictions are lifted. The development is positive but not immediately revenue-accretive, and the stock remains above the analyst target.

Analysis

The market is treating this as a regulatory optionality story, but the cleaner read is that HIMS is trying to replace an expiring, high-margin workaround with a lower-margin, more durable operating model. If peptide restrictions loosen, the upside is not near-term revenue so much as preserving customer acquisition efficiency and preventing a sharp reset in lifetime value once compounding fades. That matters because the stock is already discounting a lot of good news; the main question is whether the company can convert this into a broader chronic-care platform instead of just another temporary weight-loss trade.

Second-order beneficiaries are likely to be the supply-chain layers behind testing, telehealth workflows, and any GMP-adjacent peptide infrastructure, while the biggest losers are niche compounding channels that relied on regulatory ambiguity. The margin profile may still deteriorate even in a favorable outcome, because commercial GLP-1 fulfillment shifts the mix toward lower take rates and higher working-capital intensity. In other words, a positive FDA outcome can still be bearish for medium-term EBITDA if volume growth decelerates faster than the new product stack scales.

The contrarian setup is that the market may be overpaying for the optionality before the committee even signals its framing. The stock has been rewarded for a binary policy hope, but the path from advisory language to sustainable economics can be long and noisy, and any indication that the FDA wants tighter supervision or limited indications would likely hit the multiple first and the estimates later. On the other hand, if management can show that lab utilization and repeat engagement rise with peptide adoption, this could support a re-acceleration thesis over 2-3 quarters rather than just a one-day sentiment pop.

Key Decisions for Investors

• Fade strength in HIMS into the advisory event: sell 1-2 month calls or initiate a small tactical short against recent momentum, with a stop above the post-event gap high. Risk/reward favors a pullback if the committee outcome is merely neutral or delayed.
• If you want long exposure, prefer a defined-risk call spread in HIMS rather than stock ownership, 2-4 months out. The trade should be sized for a binary catalyst where upside is capped by already-rich expectations and downside remains material if regulatory language disappoints.
• Watch for a pair trade: long a regulated healthcare delivery name with cleaner margin visibility, short HIMS, over the next 1-2 quarters. The thesis is that HIMS faces operating leverage compression while peers with steadier reimbursement and less policy dependency de-risk earnings quality.
• Do not chase the move until after the FDA framing is clear. The best entry is a post-event dip on confirmation that peptide access expands but pricing/margin assumptions remain conservative.
• If the committee is constructive, consider a medium-term long only on evidence of rising lab volume or repeat rate improvement, not on headline approval alone. Without that second-order usage data, the incremental revenue case remains weak.